| Cas No.: | 203120-17-6 |
| Synonyms: | CS8958 |
| SMILES: | [H][C@@]1(NC(N)=N)[C@](NC(C)=O)([H])[C@@]([C@](OC)([C@@](O)([H])CO)[H])([H])OC(C(O)=O)=C1 |
| Formula: | C13H22N4O7 |
| M.Wt: | 346.34 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Publication: | [1]. Vavricka CJ, et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011 Oct;7(10):e1002249. |
| Description: | Laninamivir (R 125489) is a potent influenza neuraminidase (NA) inhibitor with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively[1]. |
| Target: | IC50: 0.90 nM (N5), 1.83 nM (p09N1), 3.12 nM (p57N2)[1] |
| In Vitro: | Laninamivir inhibits efficiently common oseltamivir-resistant viruses, including those with the ubiquitous His274Tyr substitution[1]. Laninamivir is potent against p57N2, p09N1 and N5 with a similar binding mode to Zanamivir[1]. |
| References: | [1]. Vavricka CJ, et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011 Oct;7(10):e1002249. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|
| 2018-0101 |
|